Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
7 evidence topics · 9 sources
Summary
- Indication: LEMBAZ is indicated to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in pediatric patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older.
- Position relative to other therapies: before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. In the label's integrated survival analysis, longer overall survival was observed independent of baseline miglustat use. Published recommendations state that all patients with a confirmed diagnosis should be considered for miglustat, those with neurological symptoms for levacetylleucine, and those with neurological symptoms on background miglustat for arimoclomol; more than 75% of participants in the arimoclomol and levacetylleucine pivotal trials were taking miglustat. The company describes adrabetadex as “a foundational therapy that can be safely combined with other approved NPC treatments”, based on a safety profile generally similar with and without additional therapies.
- Anticipated use: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that early intervention can make the greatest difference.
- Care setting: LEMBAZ is administered intrathecally every two weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures, with local anesthetic and sedation as indicated by the patient's clinical condition. A comprehensive audiology evaluation is performed before use. Lembaz is exclusively available through CuraScript SD by Evernorth and is billed in medical buy-and-bill settings without a product-specific HCPCS code. Published recommendations call for referral to a center with expertise in NPC wherever possible.